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myocardium. Due to this close proximity, EAT acts as metabolic 
transducer for different mediators that easily diffuse from EAT to 
vessel wall and myocardial tissue. In line, clinical studies reported 
the association of EAT thickness not only with VAT, MetS and 
relative clinical features, but also with atherosclerosis and myo-
cardial diseases (i.e. atrial fibrillation and heart failure).
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Fatty liver disease (FLD) belongs to the most frequent 
conditions in hepatology. Indeed, more than 20% of adult 
Europeans suffer from fatty liver and the incidence of this 
condition is predicted to increase even further. A subgroup of 
patients with FLD will also develop liver fibrosis, which is a 
common hallmark of chronic liver diseases. Both hepatic lipid 
accumulation, as well as, liver scarring have for long been 
expected to be modulated by the inherited predisposition. In 
the recent years genetic variants in several genes, for exam-
ple PNPLA3, TM6SF2 and MBOAT7, have been linked to 
the progression of chronic liver diseases. Prosteatotic and/or 
profibrotic variants in these genes were first detected in large 
genome- wide association studies (GWAS) and afterwards 
these associations were replicated in the following candidate 
gene analyses. In particular carriers of the PNPLA3 p.I148M 
variant have been proven to be at risk of severe liver steato-
sis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC) 
rendering variant PNPLA3 a common genetic risk factor for 
progressive liver injury. Interestingly, the same variant also 
seems to modulate the response to the FLD- therapies. The 
most recently detected splice variant rs72613567 in hydrox-
ysteroid 17- β dehydrogenase 13 (HSD17B13) seems to, in 
turn, reduce the risk of severe hepatic phenotypes. In my talk 
I will present the current knowledge on the genetic back-
ground of hepatic steatosis and fibrosis, discuss the effects of 
the known variants on the disease progression as well address 
the potential use of genetic analyses in the clinical work- up 
of patients with chronic liver diseases.
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The microbes that collectively inhabit the gut, the gut micro-
biota, constitute the largest and most diverse community in 
the body. Besides having an important role in the regulation 
of host energy metabolism, the gut microbiota can also influ-
ence neurodevelopment, modulate behavior and contribute 
to the development of neurological disorders. High- fat (HF) 
diets are thought to disrupt the profile of the gut microbiota in 
a manner that may contribute to the neuroinflammation and 
neurobehavioral changes observed in obesity. Accordingly, 
we hypothesized that by preventing HF- diet induced dysbio-
sis it is possible to prevent neuroinflammation and the conse-
quent neurological disorders.
Anthocyanins are flavonoids found in berries that exhibit 
anti- neuroinflammatory properties in the context of obesity. 
Our group has demonstrated that anthocyanins can modulate 
gut microbiota composition and counteract high- fat (HF) 
diet induced dysbiosis. In addition, we have shown that the 
modifications in gut microbial environment are partially re-
lated with the anti- neuroinflammatory properties of antho-
cyanins. Through fecal metabolome analysis, we unraveled 
the mechanism by which anthocyanins participate in the bi-
lateral communication between gut and brain. Anthocyanins 
alter host tryptophan metabolism increasing the production 
of the neuroprotective metabolite kynurenic acid. These find-
ings strongly suggest that dietary manipulation of the gut 
microbiota by anthocyanins could attenuate the neurologic 
complications of obesity, expanding the classification of psy-
chobiotics to anthocyanins.
Regarding their bioavailability, the clinical trial conducted by 
our group indicated that anthocyanins are extensively metab-
olized in the liver after absorption. Furthermore, it showed, 
for the first time, that ethanol enhances cyanidin metabolism, 
potentiating its conversion into methylated derivatives, espe-
cially in overweight and obese individuals.
These results should prompt the attention of the scientific 
community to the fact that the kinetic of these compounds is 
influenced by body composition and deserve special consid-
erations since obese individuals might be the ones who would 
benefit the most from anthocyanins intervention.
